Effects of febuxostat versus allopurinol in patients with elevated serum uric acid levels, chronic gout: A literature review
Genre
Journal articleDate
2022-03-08Author
Love, EbonyMergelsberg, Holly
Kellmyer, Alyssa
Jeganathan, Jerisan
Isa, Fadi
McGuire, James
Khan, Khurram
Labbad, Ziad G.
Department
Podiatric MedicinePodiatric Biomechanics
Permanent link to this record
http://hdl.handle.net/20.500.12613/9048Metadata
Show full item recordDOI
https://doi.org/10.55067/jifaf.v1i3.12Abstract
Gout is one of the most common etiologies of inflammatory monoarticular arthritis. Recent literature is reviewed to compare a novel advancement in chronic gout medication, febuxostat, to its counterpart allopurinol, through the identification of significant findings and improvements. Literature review concluded that febuxostat serves as a viable alternative when compared to allopurinol.Citation
Love E, Mergelsberg H, Kellmyer A, Jeganathan J, Isa F, McGuire J, Khan K, Labbad Z. Effects of febuxostat versus allopurinol in patients with elevated serum uric acid levels, chronic gout: A literature review. Journal of the International Foot & Ankle Foundation [Internet]. 2022 Mar 8;1(3). Available from: https://internationalfootankle.org/journal/index.php/JIFAF/article/view/12 doi: 10.55067/jifaf.v1i3.12Citation to related work
International Foot & Ankle FoundationHas part
The Journal of the International Foot & Ankle Foundation, Vol. 1, No. 3ADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.eduCollections
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs CC BY-NC-ND